Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases [Yahoo! Finance]
Generation Bio Co. - Common stock (GBIO)
Company Research
Source: Yahoo! Finance
Programs to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven autoimmune diseases Company reorganization supports evolution of ctLNP-enabled strategy and buildout of clinical capabilities ahead of first IND expected in 2H 2026 CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company working to change what is possible for people living with T cell-driven autoimmune diseases, announced it is leveraging its validated T cell-directed lipid nanoparticle (ctLNP) to develop siRNA therapeutics to silence disease-driving targets in T cells. “We are excited to move Generation Bio toward the clinic by deploying our ctLNP to deliver siRNA to T cells. By precisely modulating T cell activity in vivo we believe we can address high-value, currently undruggable targets involved in the inflammation and tissue damage associated with T cell-driven autoimmune diseases,” said Geoff McDonough, M.D., chief executive o
Show less
Read more
Impact Snapshot
Event Time:
GBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GBIO alerts
High impacting Generation Bio Co. - Common stock news events
Weekly update
A roundup of the hottest topics
GBIO
News
- Generation Bio Co. (NASDAQ: GBIO) had its price target lowered by analysts at Needham & Company LLC from $10.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune DiseasesGlobeNewswire
- Earnings Update: Generation Bio Co. (NASDAQ:GBIO) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts [Yahoo! Finance]Yahoo! Finance
- Generation Bio Co. (NASDAQ: GBIO) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.MarketBeat
- Generation Bio Co. (GBIO) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
GBIO
Earnings
- 8/7/24 - Miss
GBIO
Sec Filings
- 1/6/25 - Form 8-K
- 1/3/25 - Form S-8
- 12/9/24 - Form SC
- GBIO's page on the SEC website